Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Site search
Search
Toggle navigation
Contact Us
Subscribe
Promote Your Event
e-Edition
Privacy Policy
Terms of Service
Local Weather
Home Delivery
Submission Forms
News
Local News
The Leader
Heartland News
Sports
Entertainment
Local Events
Multimedia
Photo Galleries
Videos
Obituaries
Classifieds
Real Estate
Property for Rent
Cars & Vehicles
Jobs
Items for Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place an ad
Legals
Best of 2022
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ikena Oncology, Inc.
Ikena Oncology to Participate in September 2023 Investor Conferences
September 05, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Reports Second Quarter 2023 Financial Results and Corporate Update
August 10, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
August 07, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology to Participate in Upcoming Investor Conferences
May 24, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Reports First Quarter 2023 Financial Results and Highlights Advancements Across Targeted Oncology Pipeline
May 15, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Announces $40 Million Underwritten Offering
May 15, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
April 20, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meeting
April 17, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
March 07, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
March 06, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Appoints Owen Hughes as Board Chair
December 19, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
November 28, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
November 10, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
November 07, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
October 26, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
October 18, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
AZN
IKNA
Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
October 05, 2022
From
Ikena Oncology, Inc.
Via
GlobeNewswire
Tickers
IKNA
Ikena Oncology to Participate in the 2021 Jefferies Virtual Healthcare Conference
May 26, 2021
From
Ikena Oncology, Inc.
Via
Business Wire
Tickers
IKNA
Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021
May 13, 2021
From
Ikena Oncology, Inc.
Via
Business Wire
Tickers
IKNA
Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
April 15, 2021
From
Ikena Oncology, Inc.
Via
Business Wire
Tickers
IKNA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.